Waratah Capital Advisors Ltd. Sells 47,549 Shares of Danaher Corporation $DHR

Waratah Capital Advisors Ltd. reduced its stake in shares of Danaher Corporation (NYSE:DHR) by 26.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 129,394 shares of the conglomerate’s stock after selling 47,549 shares during the quarter. Danaher accounts for approximately 0.7% of Waratah Capital Advisors Ltd.’s portfolio, making the stock its 17th largest holding. Waratah Capital Advisors Ltd.’s holdings in Danaher were worth $25,560,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of DHR. Vanguard Group Inc. boosted its holdings in Danaher by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock valued at $12,296,123,000 after acquiring an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Danaher by 0.6% during the second quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock valued at $2,697,800,000 after purchasing an additional 81,670 shares during the period. Generation Investment Management LLP boosted its stake in shares of Danaher by 56.2% during the second quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after purchasing an additional 1,787,522 shares during the period. Finally, Invesco Ltd. grew its holdings in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $221.25 on Friday. The firm’s 50-day simple moving average is $205.63 and its two-hundred day simple moving average is $201.10. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The stock has a market cap of $156.28 billion, a PE ratio of 45.62, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the prior year, the business posted $1.71 EPS. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. Analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were issued a dividend of $0.32 per share. The ex-dividend date was Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Insider Transactions at Danaher

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president directly owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 29,728 shares of company stock valued at $6,448,990 in the last quarter. 11.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on DHR. Bank of America lowered their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Evercore ISI upped their price objective on shares of Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Wells Fargo & Company reissued a “positive” rating on shares of Danaher in a research note on Thursday, October 23rd. Guggenheim reaffirmed a “buy” rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Finally, TD Cowen lifted their price objective on Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Eighteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $243.39.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.